Eyre, T. A., Lamanna, N., Roeker, L. E., Ujjani, C. S., Hill, B. T., Barr, P. M., … Mato, A. R. (2021). Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica, 106(1), 284–287. https://doi.org/10.3324/haematol.2019.241539

Eyre, Toby A., Nicole Lamanna, Lindsey E. Roeker, Chaitra S. Ujjani, Brian T. Hill, Paul M. Barr, Erick Lansigan, et al. “Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.” Haematologica 106, no. 1 (January 1, 2021): 284–87. https://doi.org/10.3324/haematol.2019.241539.

Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, et al. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica. 2021 Jan 1;106(1):284–7.

Eyre, Toby A., et al. “Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.” Haematologica, vol. 106, no. 1, Jan. 2021, pp. 284–87. Pubmed, doi:10.3324/haematol.2019.241539.

Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, Islam P, Whitaker K, Coombs CC, Tuncer HH, Pagel JM, Jacobs R, Winter AM, Bailey N, Sitlinger A, Schuh AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica. 2021 Jan 1;106(1):284–287.